Table 1.

Mutations defining chromatin-spliceosome acute myeloid leukemia (CS-AML).

Driver Mutations	Pathway/Functions	Approximate Frequency (%)
		de novo AML	sAML	MDS
SRSF2	Spliceosome	2–7	12–20 *	12–17 †
SF3B1	Spliceosome	2–10	7–11 *	13–33 †
U2AF1	Spliceosome	1–4	11–16 *	5–11 †
ZRSR2	Spliceosome	0–1	3–8 *	3–8 †
STAG2	Cohesin	2–7	10–14 *	3–8 †
RUNX1	Transcription factor	5–20	20–31 *	6–14
EZH2	Chromatin modification	2–4	5–9 *	4–15 †
BCOR	Chromatin modification	2–3	7–8 *	2–6 †
ASXL1	Chromatin modification	5–15	19–32 *	10–23 †
MLL-PTD	Chromatin modification	5–8	14	4–5

* The frequency is significantly higher in secondary acute myeloid leukemia (AML) (sAML) compared with de novo AML, as previously reported [7]. † The frequency is significantly higher in myelodysplastic syndrome (MDS) compared with de novo AML, as previously reported [8].